Latest filings (excl ownership)
8-K
Other Events
1 May 24
8-K
Redemption Date Announced for Warrants
15 Apr 24
DEF 14A
Definitive proxy
26 Mar 24
ARS
2023 FY
Annual report to shareholders
22 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
28 Feb 24
8-K
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
7 Feb 24
CERT
Certification of approval for exchange listing
3 Jan 24
424B2
Prospectus for primary offering
3 Jan 24
8-A12B
Registration of securities on exchange
3 Jan 24
8-K
Entry into a Material Definitive Agreement
3 Jan 24
8-A12G
Registration of securities
2 Jan 24
8-K
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
12 Dec 23
8-K
Cassava Sciences Appoints
11 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
7 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
13 Sep 23
UPLOAD
Letter from SEC
14 Aug 23
CORRESP
Correspondence with SEC
10 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
3 Aug 23
UPLOAD
Letter from SEC
28 Jul 23
8-K
Other Events
5 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
8 May 23
8-K
Entry into a Material Definitive Agreement
1 May 23
424B5
Prospectus supplement for primary offering
1 May 23
S-3ASR
Automatic shelf registration
1 May 23
10-Q
2023 Q1
Quarterly report
1 May 23
8-K
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
1 May 23
DEF 14A
Definitive proxy
27 Mar 23
8-K
Departure of Directors or Certain Officers
16 Mar 23
ARS
2022 FY
Annual report to shareholders
16 Mar 23
PRE 14A
Preliminary proxy
16 Mar 23
8-K
Other Events
10 Mar 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
28 Feb 23
8-K
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
24 Jan 23
8-K
Amendments to Articles of Incorporation or Bylaws
22 Dec 22
8-K
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
22 Nov 22
424B5
Prospectus supplement for primary offering
21 Nov 22
Latest ownership filings
4
SANFORD ROBERTSON
30 Apr 24
4
Richard Barry
25 Apr 24
4
James William Kupiec
22 Apr 24
4
Eric Schoen
17 Apr 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BARBIER REMI
1 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
4
Claude Nicaise
8 Dec 23
3
Claude Nicaise
8 Dec 23
4
Pierre Gravier
7 Dec 23
4
Robert Eugene Anderson Jr
7 Dec 23
3
Pierre Gravier
7 Dec 23
3
Robert Eugene Anderson Jr
7 Dec 23
4
Eric Schoen
4 Oct 23
4
Robert Christopher Cook
4 Oct 23
4
James William Kupiec
4 Oct 23
4
REMI BARBIER
4 Oct 23
4
SANFORD ROBERTSON
24 Aug 23
4
Richard Barry
23 Aug 23
4
PATRICK J MD PHD SCANNON
12 Jun 23
4
REMI BARBIER
25 May 23
4
SANFORD ROBERTSON
10 May 23
4
PATRICK J MD PHD SCANNON
8 May 23
4
SANFORD ROBERTSON
8 May 23
4
DONNELL MICHAEL J O
8 May 23
4
ROBERT Z GUSSIN
8 May 23
4
Richard Barry
8 May 23
4
ROBERT Z GUSSIN
2 May 23
4
DONNELL MICHAEL J O
8 Mar 23
4
Richard Barry
8 Mar 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
SC 13G/A
CASSAVA SCIENCES / CASSAVA SCIENCES ownership change
8 Feb 23
5
REMI BARBIER
7 Feb 23
SC 13G/A
BlackRock Inc.
1 Feb 23
5
NADAV FRIEDMANN
3 Jan 23
4
Robert Christopher Cook
31 Oct 22
3
Robert Christopher Cook
31 Oct 22
4
NADAV FRIEDMANN
3 Oct 22
4
SANFORD ROBERTSON
12 Sep 22
4
Richard Barry
25 Aug 22